178results about "Cell membrane modification" patented technology

The present invention provides compositions and methods that combine the initial patterning capabilities of a direct cell printing system with the active patterning capabilities of magnetically labeled cells, such as cells labeled with superparamagnetic nanoparticles. The present invention allows for the biofabrication of a complex three-dimensional tissue scaffold comprising bioactive factors and magnetically labeled cells, which can be further manipulated after initial patterning, as well as monitored over time, and repositioned as desired, within the tissue engineering construct.

The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.

In certain aspects, the invention relates to cell delivery compositions comprising a progenitor cell and a targeting moiety, and methods related thereto. Such compositions and methods may be used, for example, in administering a targeted cell therapy to a subject.

The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.

Methods for transferring one or more proteins to a cell are disclosed. The protein or proteins to be transferred are in the form of a fusion protein, and contain at least one domain encoding for a protein or peptide having trans signaling and/or adhesion function. The fusion protein is transferred to a cell by binding to a lipidated protein, which has been incorporated into the cell membrane. In an additional aspect of the invention, methods of making fusion proteins having cis signaling capabilities, as well as the ability to bind with receptors on the cell's own surface, are provided. Fusion proteins incorporating GPI or a homing element, and a costimulator or inhibitor domain can also be directly transferred to the cell surface. Methods for using cells which have undergone protein transfer according to the present methods are also disclosed. This includes use in a cancer vaccine, use for treatment of cancer or autoimmune disease, and use in determining costimulator threshold levels.

Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis.

Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.

The present invention is directed to methods and compositions for engineering the surface of a cell, wherein a targeting moiety and/or a particle are attached to the cell membrane. The particle can further comprise a therapeutic agent for drug delivery. The compositions disclosed herein are useful in the treatment of diseased or damaged tissue by targeting cells for the purpose of tissue regeneration, drug delivery or a combination of both.

In the present invention, because no examples are known of binding of magnetic particle to mesenchymal cell or chondrocyte which might be used in regenerative medicine, whether or not a cell having the magnetic particle bound thereto is retained in local by external magnetism after administration and whether or not the cell can exhibit intrinsic activity is studied. According to the present invention, a magnetic cell comprising mesenchymal cell or cultured chondrocyte having magnetic particle bound to the surface thereof is provided, and when the cell is administered in vivo and an external magnetic field is applied, the cell can be retained for a long time at a disease site. Moreover, a drug delivery system can be constructed by causing the magnetic cells to contain a drug.

Disclosed herein are methods and materials by which nanostructures such as carbon nanotubes, nanorods, etc. are bound to lectins and/or polysaccharides and prepared for administration to cells. Also disclosed are complexes comprising glycosylated nanostructures, which bind selectively to cells expressing glycosylated surface molecules recognized by the lectin. Exemplified is a complex comprising a carbon nanotube functionalized with a lipid-like alkane, linked to a polymer bearing repeated α-N-acetylgalactosamine sugar groups. This complex is shown to selectively adhere to the surface of living cells, without toxicity. In the exemplified embodiment, adherence is mediated by a multivalent lectin, which binds both to the cells and the α-N-acetylgalactosamine groups on the nanostructure.

The present invention is directed to pegylated red blood cells comprising a polyethylene glycol (PEG) attached to a thiolated amino group on a membrane protein, and to compositions comprising the pegylated red blood cells. The invention also provides methods of preparing pegylated red blood cells comprising reacting red blood cells with a compound that produces a thiolated amino group on a red blood cell membrane protein, and reacting the thiolated red blood cell with a PEG. The invention further provides methods of treatment using pegylated red blood cells.

The present invention is drawn to a hematology control made from particles a particle having a biopolymer attached to a surface of the particle. The particle simulates a component of a blood sample, such as a reticulocyte or nucleated red blood cell component of a blood cell sample in a flow cytometer or hematology analysis instrument. The present invention is further drawn to methods of making and using the hematology control.

The present invention is directed to a non-immunogenic cellular composition comprising: a cell having a cell surface and antigenic determinants on the cell surface; an optional linker molecule covalently attached to the cell surface; and a hydrophilic, biocompatible, non-immunogenicity providing compound or polymer (e.g., polyethylene glycol or a derivative thereof) covalently attached to the linker molecule or directly to the cell. In one embodiment, the linker molecule is covalently attached directly to the antigenic determinant on the cell surface. In an alternate embodiment, the linker molecule may be covalently attached to a non-antigenic site on the cell surface, but will camouflage the antigenic determinant on the cell surface. Various uses of the resulting non-immunogenic cell are also provided, including a method of decreasing phagocytosis of a cell, a method of decreasing an adverse reaction to a transfusion, a method of decreasing rejection of a transplanted cell, tissue or organ, and a method of decreasing antibody-induced aggregation of cells.

A stirring unit for stirring a fluid contained in a vessel includes a mixing body for stirring the fluid by rotating around a rotation axis, and a magnet or a magnetic substance for receiving a rotating magnetic field for rotating the mixing body, in which a suction port and a discharge port for the fluid are provided on a surface of the mixing body, a plurality of flow paths connecting the suction port and the discharge port are provided inside the mixture, the suction port is disposed at a position on the rotation axis or at a position closer to the rotation axis than the discharge port, and the discharge port is disposed at a position outside the rotation axis than the suction port.

The invention relates to a method for modifying ligands on the surfaces of cell vesicles. The method comprises the following steps of (a) connecting diphenyl cyclooctyne onto the surfaces of the cell vesicles; (b) removing free diphenyl cyclooctyne; (c) connecting azide-modified ligands onto the diphenyl cyclooctyne on the surfaces of the cell vesicles; (d) performing purification on the modified cell vesicles. Compared with the prior art, the method has the advantages that the time is saved; the process is simple and convenient; the reaction efficiency is high; the ligand types are slightly limited; meanwhile, the physiological activity of the cell vesicles can be maintained to the maximum degree. The treatment effect of the cell vesicles can be favorably enhanced.

The present invention is directed to methods for the identification and isolation of antigen-specific T cells using a novel class of artificial antigen presenting cells. The resulting T cells may be used to produce expanded T cell populations as well as for modulating T cell responses. In general, the artificial antigen presenting cells useful in such methods are liposomes that contain MHC:peptide complexes presented on the outer surface of the liposome. Such artificial antigen presenting cells may also include accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules irrelevant to T cell binding or modulation that are used in the binding of artificial antigen presenting cells to solid support systems that may be used in the retrieval and identification of antigen-specific T cells.

A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.

A fat suited as fat phase for the manufacture of low fat spreads which are stable at elevated ambient temperatures which fat comprises a mixture of triglycerides, in which—2.5 to 5.5 wt. % of the triglycerides are HHH triglycerides,—25 to 65 wt. %, preferably 25 to 55 wt. % of the HHH triglycerides are monoacid triglycerides and the remaining HHH triglycerides are composed of mixed fatty acid residues,—1.5 to 5 wt. % of the triglycerides are HHM and HMH triglycerides,—at least 85 wt. % of the fatty acid residues H in HHM and HMH are palmitic acid residues, where H denotes saturated fatty acid residues having chain lengths larger than 15 carbon atoms and M denotes saturated fatty acid residues having chain lengths of either 12 or 14 carbon atoms and where the M-residue is placed either in the middle or in one of the terminal positions. Such fat phase can be obtained by incorporating in a triglyceride oil a fat A and a fat B where the fat A and the fat B together amount to 6-15 wt. % of the fat and the A/B weigh ratio is in the range 1/9 to 4/6, characterized in that of fat A—at least 50 wt. % of the triglycerides are fully saturated—at least 80 wt. % of the constituting saturated fatty acid residues have a chain length of 16 carbon atoms (P) or 18 carbon atoms (S), the ratio P:S being in the range 75:25-25:75,—up to 5 wt. % of the saturated fatty acid residues have a chain length of 12 or 14 carbon atoms and in that of fat B—at least 20 wt. %, preferably at least 25 wt. % of the triglycerides consist of HHM and HMH triglycerides.